Article
KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer.
Cancer research - 1 Dec 2025
Wei Yongkun, Liu Minghui, Yen Er-Yen, Yao Jun, Xun Zhenzhen, Nguyen Phuoc T, Wang Xiaofei, Yang Zecheng, Yousef Abdelrahman, Pan Dean, Jin Yanqing, Li Ching-Fei, Theardy Madelaine S, Park Jangho, Cai Yiming, Takeda Mitsunobu, Vasquez Matthew, Park Elizabeth M, Peng David H, Zhou Yong, Zhao Hong, Heffernan Timothy P, Viale Andrea, Wang Huamin, Watowich Stephanie S, Liang Han, Zhao Dan, DePinho Ronald A, Yao Wantong, Ying Haoqiang
Abstract excerpt
KRASG12C inhibitors (G12Ci) have produced encouraging, albeit modest and transient, clinical benefit in pancreatic ductal adenocarcinoma (PDAC). Identifying and targeting resistance mechanisms to G12Ci treatment are therefore crucial. To better understand the function of KRASG12C and possible G12Ci bypass mechanisms, we developed an autochthonous KRASG12C-driven PDAC model. Compared with the classical KRASG12D...
Topics
Join the communities discussing this publication.